Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-09-18

Clinical Trial Update: Treatment and Control of Atopic Dermatitis With 0.1% Tacrolimus Ointment [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating 0.1% tacrolimus ointment for the treatment of atopic dermatitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tacrolimus 0.1% ointment (tacrolimus)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Dermatitis, Atopic | Phase 3 | Status: COMPLETED